Related Experiment Videos
Poor prognosis germ cell tumors: current status and future directions
1Medical Oncology Unit, Peter MacCallum Cancer Institute, Melbourne, VIC, Australia.
Seminars in Oncology
|April 30, 1998
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2024
From imaging to action: MRI features direct surgical strategy in low rectal cancer.
Seminars in oncology·2026
Regulation of PD-1 and PD-L1 expression in tumor immune microenvironment.
Seminars in oncology·2026